{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:54:55Z","timestamp":1772582095041,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11894-025-01002-5","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T12:06:50Z","timestamp":1753186010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use?"],"prefix":"10.1007","volume":"27","author":[{"given":"Winston","family":"Dunn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1002_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"key":"1002_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347.","journal-title":"Hepatology"},{"key":"1002_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s43856-024-00649-x","volume":"4","author":"LA Diaz","year":"2024","unstructured":"Diaz LA, Lazarus JV, Fuentes-Lopez E, Idalsoaga F, Ayares G, Desaleng H, Danpanichkul P, et al. Disparities in steatosis prevalence in the united States by race or ethnicity according to the 2023 criteria. Commun Med (Lond). 2024;4:219.","journal-title":"Commun Med (Lond)"},{"key":"1002_CR4","doi-asserted-by":"publisher","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, Tatar M, Dasarathy S, Alkhouri N, Herman WH, Taksler GB, Deshpande A, et al. Estimated burden of metabolic Dysfunction-Associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8:e2454707.","journal-title":"JAMA Netw Open"},{"key":"1002_CR5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstrom H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70:1375\u201382.","journal-title":"Gut"},{"key":"1002_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and Meta-Analysis. Gastroenterology. 2020;158:1611\u201325. e1612.","journal-title":"Gastroenterology"},{"key":"1002_CR7","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","volume":"70","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the Simtuzumab trials. Hepatology. 2019;70:1913\u201327.","journal-title":"Hepatology"},{"key":"1002_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","volume":"75","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, Paradis V, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75:284\u201391.","journal-title":"J Hepatol"},{"key":"1002_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12876-024-03295-8","volume":"24","author":"N Alkhouri","year":"2024","unstructured":"Alkhouri N, Almomani A, Le P, Payne JY, Asaad I, Polanco P, Leff P, et al. The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced fibrosis and cirrhosis in the united States population utilizing AGILE 3\u2009+\u2009and AGILE 4 scores: analysis of the NHANES 2017\u20132018 cycle. BMC Gastroenterol. 2024;24:218.","journal-title":"BMC Gastroenterol"},{"key":"1002_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367\u201378. e365; quiz e314-365.","journal-title":"Gastroenterology"},{"key":"1002_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","volume":"230","author":"R Taub","year":"2013","unstructured":"Taub R, Chiang E, Chabot-Blanchet M, Kelly MJ, Reeves RA, Guertin MC, Tardif JC. Lipid Lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013;230:373\u201380.","journal-title":"Atherosclerosis"},{"key":"1002_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/hep4.1657","volume":"5","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Bashir M, Moussa SE, McCarty K, Pablo Frias J, Taub R, Alkhouri N. Effects of Resmetirom on noninvasive endpoints in a 36-Week phase 2 active treatment extension study in patients with NASH. Hepatol Commun. 2021;5:573\u201388.","journal-title":"Hepatol Commun"},{"key":"1002_CR13","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012\u201324.","journal-title":"Lancet"},{"key":"1002_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, et al. A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509.","journal-title":"N Engl J Med"},{"key":"1002_CR15","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, Alkhouri N, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29:2919\u201328.","journal-title":"Nat Med"},{"key":"1002_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","volume":"81","author":"VL Chen","year":"2025","unstructured":"Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, Kim WR. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance. Hepatology. 2025;81:312\u201320.","journal-title":"Hepatology"},{"key":"1002_CR17","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","volume":"22","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Charlton MR, Harrison SA, Bansal MB, Alkhouri N, Loomba R, Sanyal AJ, et al. Expert panel recommendations: practical clinical applications for initiating and monitoring Resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis. Clin Gastroenterol Hepatol. 2024;22:2367\u201377.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1002_CR18","unstructured":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. In: FDA News Release. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease#"},{"key":"1002_CR19","doi-asserted-by":"publisher","first-page":"19790","DOI":"10.1038\/s41598-024-70242-8","volume":"14","author":"R Suvarna","year":"2024","unstructured":"Suvarna R, Shetty S, Pappachan JM. Efficacy and safety of resmetirom, a selective thyroid hormone receptor-beta agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Sci Rep. 2024;14:19790.","journal-title":"Sci Rep"},{"key":"1002_CR20","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Stepanova M, Racila A, Henry L, Labriola D, Taub R, Nader F. Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology. 2024.","DOI":"10.1097\/HEP.0000000000001084"},{"key":"1002_CR21","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic fat reduction due to Resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin Gastroenterol Hepatol. 2022;20:1354\u201361. e1357.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1002_CR22","unstructured":"Alkhouri NMS, Sanyal AJ, Taub R, Labriola D. Noureddin use of non-invasive tests to diagnose and follow NASH with liver fibrosis patients treated with Resmetirom. M. MASH TAG 2025 Abstracts; MASHTAG.2025.A29."},{"issue":"Suppl 1","key":"1002_CR23","first-page":"TOP","volume":"80","author":"RSJ Loomba","year":"2024","unstructured":"Loomba RSJ, Taub R, Labriola D, Noureddin M, Ratziu V, Harrison SA. Paired assessment of enhanced liver fibrosis (ELF) and fibrosis-4 (FIB-4) scores is associated with an elevated risk of liver-related clinical events in participants with advanced fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). J Hepatol. 2024;80(Suppl 1):TOP\u2013265.","journal-title":"J Hepatol"},{"issue":"S1","key":"1002_CR24","first-page":"4","volume":"70","author":"NLD Chalasani","year":"2024","unstructured":"Chalasani NLD, Taub R, Anstee Q. Resmetirom effects on NASH with liver fibrosis in patients with NASH genetic risk alleles. Hepatology. 2024;70(S1):4.","journal-title":"Hepatology"},{"key":"1002_CR25","doi-asserted-by":"crossref","unstructured":"Schattenberg JMLR, Taub R, Labriola D, Harrison SA, Noureddin M. Assessment of resmetirom efficacy (80\u00a0mg vs. 100\u00a0mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial. J Hepatol. 2024;80(Suppl 1):OS-117. Presented at: EASL Congress 2024; June 5\u20138, 2024; Vienna, Austria.","DOI":"10.1016\/S0168-8278(24)00558-0"},{"key":"1002_CR26","doi-asserted-by":"crossref","unstructured":"Dunn N, Al-Khouri N, Ismail A, Singal AK. Metabolic dysfunction and alcohol-associated liver disease: A narrative review. Clin Transl Gastroenterol; 2025.","DOI":"10.14309\/ctg.0000000000000828"},{"issue":"Suppl 1","key":"1002_CR27","first-page":"SAT","volume":"80","author":"SASJ Harrison","year":"2024","unstructured":"Harrison SASJ, Taub R, Labriola D, Hill B, Ratziu V. Resmetirom treatment of a subgroup of patients with possible metaldenrolled in MAESTRO-NASH,a phase3 nash\/mashserial liver biopsy study. J Hepatol. 2024;80(Suppl 1):SAT\u2013263.","journal-title":"J Hepatol"},{"key":"1002_CR28","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.37765\/ajmc.2024.89635","volume":"30","author":"N Alkhouri","year":"2024","unstructured":"Alkhouri N, Noureddin M. Management strategies for metabolic dysfunction-associated steatotic liver disease (MASLD). Am J Manag Care. 2024;30:S159\u201374.","journal-title":"Am J Manag Care"},{"key":"1002_CR29","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/13543784.2024.2441865","volume":"33","author":"E Kaya","year":"2024","unstructured":"Kaya E, Yilmaz Y, Alkhouri N. Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction. Expert Opin Investig Drugs. 2024;33:1167\u201376.","journal-title":"Expert Opin Investig Drugs"},{"key":"1002_CR30","unstructured":"Noureddin MRM, Taub R, Labriola D, Alkhouri N, Bansal M, Effect of resmetirom or, placebo in nash fibrosis patients with\u2009=\u20095% weight lossand\/or on baseline GLP-1 therapy in the maestro-nash 52 week serial liver biopsy study. Hepatology. 2024;70(S1):112;Hepatology. 2024;70(S1):112."},{"key":"1002_CR31","unstructured":"Le PDS, Herman W, Ye W, Welch N, Criswell V, Rothberg M, Value-based pricing, of resmetirom for the treatment of metabolic dysfunction-associated steatotic liver disease: a cost-effectiveness analysis. Hepatology. 2024;70(S1):228."},{"key":"1002_CR32","unstructured":"McRae MPTR, Everson GT. Resmetirom therapy of MASH-Associated child Pugh A cirrhosis reduces estimated risk for clinical outcome based on hepquant RISK ACE model. MASH TAG 2025 Abstracts; MASHTAG.2025.A21."},{"key":"1002_CR33","unstructured":"N. A. General characteristics of the patients prescribed resmetirom: data derived from six tertiary care centers in the united states. Poster presented at: EASL Congress 2025; 2025 May 7\u201310; Amsterdam, Netherlands. Abstract 1221."}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01002-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-025-01002-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01002-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:03:46Z","timestamp":1772579026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-025-01002-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1007\/s11894-025-01002-5","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"15 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests. W.D has received grant\/research support from 89bio, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, Novo Nordisk; reports speaker\u2019s fees from Gilead Sciences and Madrigal Pharmaceuticals; and reports consulting for Ipsen and Novo Nordisk. N.A. has received grant\/research support from 89bio, Akero Therapeutics, Arbutus Biopharma, AstraZeneca, BioAge, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Galectin Therapeutics, Genentech, Gilead Sciences, Hepagene Therapeutics, Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Lilly, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, PharmaIN, Poxel, Regeneron, Viking Therapeutics, and Zydus Pharmaceuticals; reports speaker\u2019s fees from AbbVie, AstraZeneca, Echosens, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, and Perspectum; and reports consulting for 89bio, AbbVie, Akero, Boehringer Ingelheim, Echosens, Fibronostics, Gilead Sciences, HistoIndex, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, and Regeneron.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"53"}}